While previous reports have shown independent prognostic value of RUNX1 and ASXL1, some focused only on cytogenetically normal AML without adjusting for NPM1 and biallelic CEBPA in multivariable models26,29, while in other reports, the impact on OS was lost when adjusted for these mutations25,27,30. This evidence concerns the gene NPM1 and acute myeloid leukemia.